Infinity Announces Appointment of Dr. Thomas J. Lynch to Its Board of Directors
CAMBRIDGE, Mass., Oct. 7, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, announced today that Thomas J. Lynch, Jr., M.D., has been appointed to its Board of Directors.
Dr. Lynch is the Director of the Yale Cancer Center and the Physician-in-Chief at Smilow Cancer Hospital at Yale-New Haven. He has focused his career on the care and treatment of patients with lung cancer and the clinical development of novel agents targeting lung cancer. Recently, his work has focused on agents directed against the epidermal growth factor receptor (EGFR) and the potential role that EGFR mutations play in lung cancer biology. Prior to 2009, Dr. Lynch was the Chief of Hematology-Oncology at Massachusetts General Hospital (MGH) and a Professor of Medicine at Harvard Medical School. He received his M.D. from Yale University and completed his internship and residency at MGH. Before joining the staff at MGH, Dr. Lynch served as a fellow in medical oncology at the Dana-Farber Cancer Institute. Dr. Lynch is a founding board member and vice chair of the board of the Kenneth B. Schwartz Center, a foundation devoted to promoting compassionate health care.
"Infinity is delighted to welcome Dr. Lynch to our Board of Directors," said Steven H. Holtzman, chair and chief executive officer, Infinity. "Dr. Lynch's professional reputation, extensive experience in clinical oncology, particularly in lung cancer, and passion for patients position him to be a valuable asset to, and have an immediate impact on, our organization."
"I am pleased to be joining Infinity's Board of Directors," said Dr. Lynch. "I look forward to being part of Infinity's current and future efforts to successfully develop novel treatments for patients with cancer."
About Infinity Pharmaceuticals, Inc.
Infinity is an innovative cancer drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging cancer pathways. Infinity's two most advanced programs in Hsp90 chaperone inhibition and Hedgehog signaling pathway inhibition are evidence of its innovative approach to oncology drug discovery and development. For more information on Infinity, please refer to the company's website at http://www.infi.com.